These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

653 related articles for article (PubMed ID: 32210089)

  • 1. Glucose and Blood Pressure-Dependent Pathways-The Progression of Diabetic Kidney Disease.
    Patel DM; Bose M; Cooper ME
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32210089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update of pathophysiology and management of diabetic kidney disease.
    Lin YC; Chang YH; Yang SY; Wu KD; Chu TS
    J Formos Med Assoc; 2018 Aug; 117(8):662-675. PubMed ID: 29486908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetic nephropathy: where hemodynamics meets metabolism.
    Forbes JM; Fukami K; Cooper ME
    Exp Clin Endocrinol Diabetes; 2007 Feb; 115(2):69-84. PubMed ID: 17318765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies.
    Warren AM; Knudsen ST; Cooper ME
    Expert Opin Ther Targets; 2019 Jul; 23(7):579-591. PubMed ID: 31154867
    [No Abstract]   [Full Text] [Related]  

  • 5. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
    Zou H; Zhou B; Xu G
    Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on diagnosis, pathophysiology, and management of diabetic kidney disease.
    Sugahara M; Pak WLW; Tanaka T; Tang SCW; Nangaku M
    Nephrology (Carlton); 2021 Jun; 26(6):491-500. PubMed ID: 33550672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.
    Koszegi S; Molnar A; Lenart L; Hodrea J; Balogh DB; Lakat T; Szkibinszkij E; Hosszu A; Sparding N; Genovese F; Wagner L; Vannay A; Szabo AJ; Fekete A
    J Physiol; 2019 Jan; 597(1):193-209. PubMed ID: 30324679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
    Feng Y; Huang R; Kavanagh J; Li L; Zeng X; Li Y; Fu P
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):259-286. PubMed ID: 30737754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetic Kidney Disease.
    Bonner R; Albajrami O; Hudspeth J; Upadhyay A
    Prim Care; 2020 Dec; 47(4):645-659. PubMed ID: 33121634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Diabetic Kidney Disease With Hypertension Control and Renin Angiotensin System Inhibition.
    Patney V; Chaudhary K; Whaley-Connell A
    Adv Chronic Kidney Dis; 2018 Mar; 25(2):158-165. PubMed ID: 29580580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel therapeutic agents for the treatment of diabetic kidney disease.
    Hartman RE; Rao PSS; Churchwell MD; Lewis SJ
    Expert Opin Investig Drugs; 2020 Nov; 29(11):1277-1293. PubMed ID: 32799584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets.
    Barrera-Chimal J; Jaisser F
    Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():16-31. PubMed ID: 32267077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT-2 inhibitors in Diabetic Kidney Disease: What Lies Behind their Renoprotective Properties?
    Georgianos PI; Divani M; Eleftheriadis T; Mertens PR; Liakopoulos V
    Curr Med Chem; 2019; 26(29):5564-5578. PubMed ID: 29792136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of progression of diabetic kidney disease mediated by podocyte mitochondrial injury.
    Su J; Ye D; Gao C; Huang Q; Gui D
    Mol Biol Rep; 2020 Oct; 47(10):8023-8035. PubMed ID: 32918716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases.
    Huang W; Chen YY; Li ZQ; He FF; Zhang C
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose- and Non-Glucose-Induced Mitochondrial Dysfunction in Diabetic Kidney Disease.
    Ito M; Gurumani MZ; Merscher S; Fornoni A
    Biomolecules; 2022 Feb; 12(3):. PubMed ID: 35327540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.
    Parving HH; Andersen S; Jacobsen P; Christensen PK; Rossing K; Hovind P; Rossing P; Tarnow L
    Semin Nephrol; 2004 Mar; 24(2):147-57. PubMed ID: 15017527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment.
    Weir MR
    Postgrad Med; 2019 Aug; 131(6):367-375. PubMed ID: 31132013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on role of direct renin inhibitor in diabetic kidney disease.
    Dhakarwal P; Agrawal V; Kumar A; Goli KM; Agrawal V
    Ren Fail; 2014 Jul; 36(6):963-9. PubMed ID: 24678880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.